Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.

By Antoni Ribas, O. Hamid, A. Daud, F. Hodi, J. Wolchok, R. Kefford, A. Joshua, A. Patnaik, W. Hwu, J. Weber and 18 more. Journal of the American Medical Association (JAMA), 2016

1,024 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/72112ff77736df9608cfd15a1bbf3617f5558a2c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. J. Wolchok
2. C. Robert
3. B. Berent-Maoz
4. T. Graeber
5. Catherine S. Grasso
6. D. Pardoll

In Oncology

1. J. Wolchok
2. Antoni Ribas
3. C. Robert
4. F. Hodi
5. K. Flaherty
6. D. Barbie
7. Russell W. Jenkins
8. D. Pardoll

Citations in the corpus

• Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 (2019, methodology): “Eligibility criteria for the ipilimumab-treated or ipilimumab-naive melanoma cohorts are published [8].”
• Mechanisms of resistance to immune checkpoint inhibitors (2018, background): “Expansion of intratumoural T(EM) in response to PD-1 blockade has been demonstrated, and is more pronounced in patients responding to therapy (Ribas et al, 2016b), suggesting a key role for TEM cells in anti-PD-1 action and clinical response (O’Donnell et al, 2017).”
• DE NOVO EPIGENETIC PROGRAMS INHIBIT PD-1 BLOCKADE-MEDIATED T-CELL REJUVENATION (2017, neutral): “In a recent clinical trial utilizing ICB for melanoma treatment, about one-third of patients who initially responded to PD-1 blockade experienced tumor relapse (Ribas et al., 2016).”
• Primary resistance to PD-1 blockade mediated by JAK1/2 mutations (2016, methodology): “Tumor samples Tumor biopsies were obtained from a subset of patients enrolled in a phase 1 expansion clinical trial with pembrolizumab after signing a written informed consent (32).”
• Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (2017, neutral): “%) and chills (29%), which are anticipated with this agent (Ribas et al., 2016).”
• Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018, background): “In melanoma, antiPD-1 treatment was more effective in patients with smaller tumors (66).”